Brevinor-1 Australia - English - Department of Health (Therapeutic Goods Administration)

brevinor-1

ethinyloestradiol; norethisterone -

Loette Australia - English - Department of Health (Therapeutic Goods Administration)

loette

pfizer australia pty ltd - ethinyloestradiol; levonorgestrel -

MICROGYNON 20 ED Australia - English - Department of Health (Therapeutic Goods Administration)

microgynon 20 ed

bayer australia ltd - ethinyloestradiol; levonorgestrel -

MICROLEVLEN ED Australia - English - Department of Health (Therapeutic Goods Administration)

microlevlen ed

bayer australia ltd - ethinyloestradiol; levonorgestrel -

Estraderm Australia - English - Department of Health (Therapeutic Goods Administration)

estraderm

novartis pharmaceuticals australia pty ltd - oestradiol -

Estalis Sequi Australia - English - Department of Health (Therapeutic Goods Administration)

estalis sequi

novartis pharmaceuticals australia pty ltd - oestradiol; norethisterone acetate -

Femoston Australia - English - Department of Health (Therapeutic Goods Administration)

femoston

abbott australasia pty ltd - oestradiol; dydrogesterone -

Estalis Continuous New Zealand - English - Medsafe (Medicines Safety Authority)

estalis continuous

sandoz new zealand limited - estradiol hemihydrate 0.62mg equivalent to oestradiol 50 µg/24 hours;  ; norethisterone acetate 2.7mg equivalent to norethisterone acetate 140 µg/24 hours;   - transdermal patch - 50/140 - active: estradiol hemihydrate 0.62mg equivalent to oestradiol 50 µg/24 hours   norethisterone acetate 2.7mg equivalent to norethisterone acetate 140 µg/24 hours   excipient: acrylic adhesive dipropylene glycol oleic acid povidone silicone adhesive - treatment of symptoms of oestrogen deficiency in postmenopausal women with an intact uterus. prevention of osteoporosis in postmenopausal women with an intact uterus.

Estalis Continuous New Zealand - English - Medsafe (Medicines Safety Authority)

estalis continuous

sandoz new zealand limited - estradiol hemihydrate 0.512mg equivalent to oestradiol 50 µg/24 hours;  ; norethisterone acetate 4.8mg equivalent to norethisterone acetate 250 µg/24 hours;   - transdermal patch - 50/250 - active: estradiol hemihydrate 0.512mg equivalent to oestradiol 50 µg/24 hours   norethisterone acetate 4.8mg equivalent to norethisterone acetate 250 µg/24 hours   excipient: acrylic adhesive dipropylene glycol oleic acid povidone silicone adhesive - treatment of symptoms of oestrogen deficiency in postmenopausal women with an intact uterus. prevention of osteoporosis in postmenopausal women with an intact uterus.

Zumenon Australia - English - Department of Health (Therapeutic Goods Administration)

zumenon

abbott australasia pty ltd - oestradiol hemihydrate -